메뉴 건너뛰기




Volumn 177, Issue 2, 2014, Pages 439-453

Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients

Author keywords

Immunoregulation; Lenalidomide; MDSCs; Multiple myeloma; T cells

Indexed keywords

CD14 ANTIGEN; CD15 ANTIGEN; CD8 ANTIGEN; GRANZYME; LENALIDOMIDE; PERFORIN;

EID: 84903957798     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12343     Document Type: Article
Times cited : (50)

References (46)
  • 1
    • 42449114035 scopus 로고    scopus 로고
    • Multiple myeloma
    • Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008; 111:2962-2972.
    • (2008) Blood , vol.111 , pp. 2962-2972
    • Kyle, R.A.1    Rajkumar, S.V.2
  • 2
    • 0033454740 scopus 로고    scopus 로고
    • Transforming growth factor beta from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes
    • Cook G, Campbell JD, Carr CE, Boyd KS, Franklin IM. Transforming growth factor beta from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes. J Leukoc Biol 1999; 66:981-988.
    • (1999) J Leukoc Biol , vol.66 , pp. 981-988
    • Cook, G.1    Campbell, J.D.2    Carr, C.E.3    Boyd, K.S.4    Franklin, I.M.5
  • 3
    • 34347400169 scopus 로고    scopus 로고
    • Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway
    • Liu J, Hamrouni A, Wolowiec D etal. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007; 110:296-304.
    • (2007) Blood , vol.110 , pp. 296-304
    • Liu, J.1    Hamrouni, A.2    Wolowiec, D.3
  • 4
    • 0035892109 scopus 로고    scopus 로고
    • Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10
    • Brown RD, Pope B, Murray A etal. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 2001; 98:2992-2998.
    • (2001) Blood , vol.98 , pp. 2992-2998
    • Brown, R.D.1    Pope, B.2    Murray, A.3
  • 5
    • 33644757687 scopus 로고    scopus 로고
    • Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma
    • Wang S, Yang J, Qian J, Wezeman M, Kwak LW, Yi Q. Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood 2006; 107:2432-2439.
    • (2006) Blood , vol.107 , pp. 2432-2439
    • Wang, S.1    Yang, J.2    Qian, J.3    Wezeman, M.4    Kwak, L.W.5    Yi, Q.6
  • 6
    • 0842265594 scopus 로고    scopus 로고
    • Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage
    • Mozaffari F, Hansson L, Kiaii S etal. Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage. Br J Haematol 2004; 124:315-324.
    • (2004) Br J Haematol , vol.124 , pp. 315-324
    • Mozaffari, F.1    Hansson, L.2    Kiaii, S.3
  • 7
    • 58849093606 scopus 로고    scopus 로고
    • CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) double negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden
    • Feyler S, von Lilienfeld-Toal M, Jarmin S etal. CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) double negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol 2009; 144:686-695.
    • (2009) Br J Haematol , vol.144 , pp. 686-695
    • Feyler, S.1    von Lilienfeld-Toal, M.2    Jarmin, S.3
  • 8
    • 33646575622 scopus 로고    scopus 로고
    • In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma
    • Beyer M, Kochanek M, Giese T etal. In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood 2006; 107:3940-3949.
    • (2006) Blood , vol.107 , pp. 3940-3949
    • Beyer, M.1    Kochanek, M.2    Giese, T.3
  • 9
    • 77953111633 scopus 로고    scopus 로고
    • Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked
    • von Lilienfeld-Toal M, Frank S, Leyendecker C etal. Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked. Cancer Immunol Immunother 2010; 59:829-839.
    • (2010) Cancer Immunol Immunother , vol.59 , pp. 829-839
    • von Lilienfeld-Toal, M.1    Frank, S.2    Leyendecker, C.3
  • 10
    • 39549084084 scopus 로고    scopus 로고
    • MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma
    • Jinushi M, Vanneman M, Munshi NC etal. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci USA 2008; 105:1285-1290.
    • (2008) Proc Natl Acad Sci USA , vol.105 , pp. 1285-1290
    • Jinushi, M.1    Vanneman, M.2    Munshi, N.C.3
  • 11
    • 77951258918 scopus 로고    scopus 로고
    • Myeloid-derived suppressor cell heterogeneity and subset definition
    • Peranzoni E, Zilio S, Marigo I etal. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010; 22:238-244.
    • (2010) Curr Opin Immunol , vol.22 , pp. 238-244
    • Peranzoni, E.1    Zilio, S.2    Marigo, I.3
  • 12
    • 61349100687 scopus 로고    scopus 로고
    • Myeloid-derived suppressor cells as regulators of the immune system
    • Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-174.
    • (2009) Nat Rev Immunol , vol.9 , pp. 162-174
    • Gabrilovich, D.I.1    Nagaraj, S.2
  • 13
    • 79955740671 scopus 로고    scopus 로고
    • Myeloid-derived suppressor cells-their role in haemato-oncological malignancies and other cancers and possible implications for therapy
    • Tadmor T, Attias D, Polliack A. Myeloid-derived suppressor cells-their role in haemato-oncological malignancies and other cancers and possible implications for therapy. Br J Haematol 2011; 153:557-567.
    • (2011) Br J Haematol , vol.153 , pp. 557-567
    • Tadmor, T.1    Attias, D.2    Polliack, A.3
  • 14
    • 78149270433 scopus 로고    scopus 로고
    • Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma
    • Brimnes MK, Vangsted AJ, Knudsen LM etal. Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand J Immunol 2010; 72:540-547.
    • (2010) Scand J Immunol , vol.72 , pp. 540-547
    • Brimnes, M.K.1    Vangsted, A.J.2    Knudsen, L.M.3
  • 15
    • 84879452593 scopus 로고    scopus 로고
    • Tumor promoting immune suppressive myeloid derived suppressor cells in multiple myeloma microenvironment
    • Gorgun GT, Whitehill G, Anderson JL etal. Tumor promoting immune suppressive myeloid derived suppressor cells in multiple myeloma microenvironment. Blood 2013; 121:2975-2987.
    • (2013) Blood , vol.121 , pp. 2975-2987
    • Gorgun, G.T.1    Whitehill, G.2    Anderson, J.L.3
  • 16
    • 84860709392 scopus 로고    scopus 로고
    • Lenalidomide maintenance after stem-cell transplantation for multiple myeloma
    • Attal M, Lauwers-Cances V, Marit G etal. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366:1782-1791.
    • (2012) N Engl J Med , vol.366 , pp. 1782-1791
    • Attal, M.1    Lauwers-Cances, V.2    Marit, G.3
  • 17
    • 33846665934 scopus 로고    scopus 로고
    • Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells
    • Verhelle D, Corral LG, Wong K etal. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007; 67:746-755.
    • (2007) Cancer Res , vol.67 , pp. 746-755
    • Verhelle, D.1    Corral, L.G.2    Wong, K.3
  • 18
    • 77950644007 scopus 로고    scopus 로고
    • Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function
    • Gandhi AK, Kang J, Capone L etal. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010; 10:155-167.
    • (2010) Curr Cancer Drug Targets , vol.10 , pp. 155-167
    • Gandhi, A.K.1    Kang, J.2    Capone, L.3
  • 19
    • 84868599212 scopus 로고    scopus 로고
    • Current treatment strategies with lenalidomide in multiple myeloma and future perspectives
    • Larocca A, Cavallo F, Mina R, Boccadoro M, Palumbo A. Current treatment strategies with lenalidomide in multiple myeloma and future perspectives. Future Oncol 2012; 8:1223-1238.
    • (2012) Future Oncol , vol.8 , pp. 1223-1238
    • Larocca, A.1    Cavallo, F.2    Mina, R.3    Boccadoro, M.4    Palumbo, A.5
  • 20
    • 36349010285 scopus 로고    scopus 로고
    • Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
    • Weber DM, Chen C, Niesvizky R etal. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357:2133-2142.
    • (2007) N Engl J Med , vol.357 , pp. 2133-2142
    • Weber, D.M.1    Chen, C.2    Niesvizky, R.3
  • 21
    • 27744492561 scopus 로고    scopus 로고
    • Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
    • Rajkumar SV, Hayman SR, Lacy MQ etal. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106:4050-4053.
    • (2005) Blood , vol.106 , pp. 4050-4053
    • Rajkumar, S.V.1    Hayman, S.R.2    Lacy, M.Q.3
  • 22
    • 84866169745 scopus 로고    scopus 로고
    • Expansion of polyfunctional HIV-specific T cells upon stimulation with mRNA electroporated dendritic cells in the presence of immunomodulatory drugs
    • De Keersmaecker B, Allard SD, Lacor P, Schots R, Thielemans K, Aerts JL. Expansion of polyfunctional HIV-specific T cells upon stimulation with mRNA electroporated dendritic cells in the presence of immunomodulatory drugs. J Virol 2012; 86:9351-9360.
    • (2012) J Virol , vol.86 , pp. 9351-9360
    • De Keersmaecker, B.1    Allard, S.D.2    Lacor, P.3    Schots, R.4    Thielemans, K.5    Aerts, J.L.6
  • 23
    • 79960494739 scopus 로고    scopus 로고
    • Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma
    • Neuber B, Herth I, Tolliver C etal. Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma. J Immunol 2011; 187:1047-1056.
    • (2011) J Immunol , vol.187 , pp. 1047-1056
    • Neuber, B.1    Herth, I.2    Tolliver, C.3
  • 24
    • 84857770908 scopus 로고    scopus 로고
    • Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses
    • Noonan K, Rudraraju L, Ferguson A etal. Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses. Clin Cancer Res 2012; 18:1426-1434.
    • (2012) Clin Cancer Res , vol.18 , pp. 1426-1434
    • Noonan, K.1    Rudraraju, L.2    Ferguson, A.3
  • 25
    • 0035412366 scopus 로고    scopus 로고
    • Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
    • Davies FE, Raje N, Hideshima T etal. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98:210-216.
    • (2001) Blood , vol.98 , pp. 210-216
    • Davies, F.E.1    Raje, N.2    Hideshima, T.3
  • 26
    • 76749162262 scopus 로고    scopus 로고
    • Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells
    • Lioznov M, El-Cheikh J Jr, Hoffmann F etal. Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells. Bone Marrow Transplant 2010; 45:349-353.
    • (2010) Bone Marrow Transplant , vol.45 , pp. 349-353
    • Lioznov, M.1    El-Cheikh Jr, J.2    Hoffmann, F.3
  • 27
    • 84873486267 scopus 로고    scopus 로고
    • Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: results from a phase I/II dose-finding study
    • Wolschke C, Stubig T, Hegenbart U etal. Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: results from a phase I/II dose-finding study. Exp Hematol 2012; 41:134-142.
    • (2012) Exp Hematol , vol.41 , pp. 134-142
    • Wolschke, C.1    Stubig, T.2    Hegenbart, U.3
  • 28
    • 80052398586 scopus 로고    scopus 로고
    • Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial
    • Kneppers E, van der Holt B, Kersten MJ etal. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood 2011; 118:2413-2419.
    • (2011) Blood , vol.118 , pp. 2413-2419
    • Kneppers, E.1    van der Holt, B.2    Kersten, M.J.3
  • 29
    • 84865838005 scopus 로고    scopus 로고
    • Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial
    • Sockel K, Bornhaeuser M, Mischak-Weissinger E etal. Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial. Haematologica 2012; 97:e34-35.
    • (2012) Haematologica , vol.97
    • Sockel, K.1    Bornhaeuser, M.2    Mischak-Weissinger, E.3
  • 30
    • 2142730100 scopus 로고    scopus 로고
    • Central memory and effector memory T cell subsets: function, generation, and maintenance
    • Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004; 22:745-763.
    • (2004) Annu Rev Immunol , vol.22 , pp. 745-763
    • Sallusto, F.1    Geginat, J.2    Lanzavecchia, A.3
  • 31
    • 55949116720 scopus 로고    scopus 로고
    • Phenotype and function of human T lymphocyte subsets: consensus and issues
    • Appay V, van Lier RA, Sallusto F, Roederer M. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A 2008; 73:975-983.
    • (2008) Cytometry A , vol.73 , pp. 975-983
    • Appay, V.1    van Lier, R.A.2    Sallusto, F.3    Roederer, M.4
  • 32
    • 0002838124 scopus 로고
    • Alterations in function and phenotype of monocytes from patients with septic disease-predictive value and new therapeutic strategies
    • In Faist E, Meakins JL, Schildberg FW, eds. Berlin/Heidelberg, Germany: Springer-Verlag
    • Volk HD, Thieme M, Heym S etal. Alterations in function and phenotype of monocytes from patients with septic disease-predictive value and new therapeutic strategies. In Faist E, Meakins JL, Schildberg FW, eds. Host defense dysfunction in trauma, shock, and sepsis. Berlin/Heidelberg, Germany: Springer-Verlag, 1993:365-371.
    • (1993) Host defense dysfunction in trauma, shock, and sepsis , pp. 365-371
    • Volk, H.D.1    Thieme, M.2    Heym, S.3
  • 33
    • 0029417843 scopus 로고
    • Very low monocytic HLA-DR expression indicates high risk of infection-immunomonitoring for patients after neurosurgery and patients during high dose steroid therapy
    • Asadullah K, Woiciechowsky C, Docke WD etal. Very low monocytic HLA-DR expression indicates high risk of infection-immunomonitoring for patients after neurosurgery and patients during high dose steroid therapy. Eur J Emerg Med 1995; 2:184-190.
    • (1995) Eur J Emerg Med , vol.2 , pp. 184-190
    • Asadullah, K.1    Woiciechowsky, C.2    Docke, W.D.3
  • 34
    • 33745201174 scopus 로고    scopus 로고
    • Monocyte HLA-DR and interferon-gamma treatment in severely injured patients-a critical reappraisal more than a decade later
    • Turina M, Dickinson A, Gardner S, Polk HC Jr. Monocyte HLA-DR and interferon-gamma treatment in severely injured patients-a critical reappraisal more than a decade later. J Am Coll Surg 2006; 203:73-81.
    • (2006) J Am Coll Surg , vol.203 , pp. 73-81
    • Turina, M.1    Dickinson, A.2    Gardner, S.3    Polk Jr, H.C.4
  • 35
    • 0029823055 scopus 로고    scopus 로고
    • Monocyte deactivation-rationale for a new therapeutic strategy in sepsis
    • Volk HD, Reinke P, Krausch D etal. Monocyte deactivation-rationale for a new therapeutic strategy in sepsis. Intensive Care Med 1996; 22 (Suppl. 4):S474-481.
    • (1996) Intensive Care Med , vol.22 , Issue.SUPPL. 4
    • Volk, H.D.1    Reinke, P.2    Krausch, D.3
  • 36
    • 46049098560 scopus 로고    scopus 로고
    • A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells
    • Hoechst B, Ormandy LA, Ballmaier M etal. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008; 135:234-243.
    • (2008) Gastroenterology , vol.135 , pp. 234-243
    • Hoechst, B.1    Ormandy, L.A.2    Ballmaier, M.3
  • 37
    • 77953141534 scopus 로고    scopus 로고
    • Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign
    • Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 2010; 70:4335-4345.
    • (2010) Cancer Res , vol.70 , pp. 4335-4345
    • Poschke, I.1    Mougiakakos, D.2    Hansson, J.3    Masucci, G.V.4    Kiessling, R.5
  • 38
    • 70349240416 scopus 로고    scopus 로고
    • Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor
    • Hoechst B, Voigtlaender T, Ormandy L etal. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 2009; 50:799-807.
    • (2009) Hepatology , vol.50 , pp. 799-807
    • Hoechst, B.1    Voigtlaender, T.2    Ormandy, L.3
  • 39
    • 34447258415 scopus 로고    scopus 로고
    • Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine
    • Filipazzi P, Valenti R, Huber V etal. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007; 25:2546-2553.
    • (2007) J Clin Oncol , vol.25 , pp. 2546-2553
    • Filipazzi, P.1    Valenti, R.2    Huber, V.3
  • 40
    • 76149145359 scopus 로고    scopus 로고
    • Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer
    • Vuk-Pavlovic S, Bulur PA, Lin Y etal. Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer. Prostate 2010; 70:443-455.
    • (2010) Prostate , vol.70 , pp. 443-455
    • Vuk-Pavlovic, S.1    Bulur, P.A.2    Lin, Y.3
  • 42
    • 84862006649 scopus 로고    scopus 로고
    • Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation
    • McDaniel JM, Zou JX, Fulp W, Chen DT, List AF, Epling-Burnette PK. Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation. Leukemia 2012; 26:1425-1429.
    • (2012) Leukemia , vol.26 , pp. 1425-1429
    • McDaniel, J.M.1    Zou, J.X.2    Fulp, W.3    Chen, D.T.4    List, A.F.5    Epling-Burnette, P.K.6
  • 43
    • 62549095932 scopus 로고    scopus 로고
    • Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells
    • Minnema MC, van der Veer MS, Aarts T, Emmelot M, Mutis T, Lokhorst HM. Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells. Leukemia 2009; 23:605-607.
    • (2009) Leukemia , vol.23 , pp. 605-607
    • Minnema, M.C.1    van der Veer, M.S.2    Aarts, T.3    Emmelot, M.4    Mutis, T.5    Lokhorst, H.M.6
  • 44
    • 67349107194 scopus 로고    scopus 로고
    • The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
    • Galustian C, Meyer B, Labarthe MC etal. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009; 58:1033-1045.
    • (2009) Cancer Immunol Immunother , vol.58 , pp. 1033-1045
    • Galustian, C.1    Meyer, B.2    Labarthe, M.C.3
  • 45
    • 70350133511 scopus 로고    scopus 로고
    • IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients
    • Mandruzzato S, Solito S, Falisi E etal. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol 2009; 182:6562-6568.
    • (2009) J Immunol , vol.182 , pp. 6562-6568
    • Mandruzzato, S.1    Solito, S.2    Falisi, E.3
  • 46
    • 79251597893 scopus 로고    scopus 로고
    • Preferential enhancement of older human T cell cytokine generation, chemotaxis, proliferation and survival by lenalidomide
    • Huang MC, Greig NH, Luo W etal. Preferential enhancement of older human T cell cytokine generation, chemotaxis, proliferation and survival by lenalidomide. Clin Immunol 2011; 138:201-211.
    • (2011) Clin Immunol , vol.138 , pp. 201-211
    • Huang, M.C.1    Greig, N.H.2    Luo, W.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.